Intelligent Medical Oxygen Delivery system – IMOD®

Advancing oxygen therapy through precise,
intelligent flow control


Using Binary Actuation Technology (BAT), IMOD® is the only responsive oxygen delivery device able to monitor and automatically adjust to a patient’s individual oxygen needs and requirements.

IMOD® receives oxygen from a bottled or bulk supply and reactively delivers the correct dose through a nasal cannula or a face mask, the first in its class to do so. The ultra-sensitive breath-detection system at the heart of IMOD®, enabled by BAT, tracks the user’s breathing pattern and delivers oxygen even with the slightest inhalation.

Discover the features and benefits of IMOD®

Oxygen therapy is required for a broad range of respiratory and non-respiratory diseases such as anaemia, lung cancer, anaphylaxis, post-surgery while the patient is recovering from anaesthesia and emergency medicine. Only 69% of patients using emergency oxygen maintain a saturation within the intended prescribed range.1

Respiratory Consultants from Royal Derby hospital estimate 2000 to 4000 patients a year in the UK are “killed unnecessarily by incorrect oxygen supply”.2 Developed in collaboration with leading clinicians, the IMOD® system offers significant clinical benefits while dramatically improving patient experience and reducing the consumption of medical oxygen by two thirds.

Quality of Life Benefits

Improved quality of life and superior patient comfort.3,4

Delivers oxygen to maintain a prescribed oxygen saturation

Supplies oxygen only during inhalation, which means that oxygen bottles last three times as long

Follows changes in breathing rate

The only oxygen conserving device to work with either a facemask in addition to a nasal cannula, improving patient comfort

Operates from piped supply or bottles, therefore versatile

Has extensive safety features

Has up to 40 hours battery life

Discover More

The IMOD® system only delivers oxygen during inhalation, resulting in oxygen cylinders lasting approximately three times longer than normal. With this feature, the IMOD® system saves up to 66% of oxygen consumption compared to continuous supply, eliminating the need to change oxygen bottles frequently.

IMOD® is compact and portable, allowing easy transportation and will run continuously for a minimum of 24 hours on a single, mobile-phone like charge

Clinical Benefits

Immediate clinical benefit through prevention
of over-consumption and optimum blood oxygen concentration.4,5

Accurate and diverse monitoring capabilities
Breath synchronised mode
IMOD® can deliver up to 15 litres of oxygen per minute

Discover More

IMOD® can monitor blood-oxygen concentration (SpO2) and automatically adjust to prescribed levels, while recording vital readings to provide valuable clinical data.

IMOD® can be set to supply in continuous or breath-synchronised mode.

IMOD® works seamlessly with all breathing accessories:

Non-rebreather face mask
Venturi face mask
Standard face mask
Nasal cannula

An IMOD® system may be transferred from a bulk supply to a bottle supply, and vice-versa.

In an emergency setting IMOD® can be used to prevent services running out of gas, potentially extending the duration and range of transfer to the most suitable hospital.

Cost benefits

Significant cost savings through reduction of waste and increased efficiency. 5

Expected oxygen saving of up to 66% compared to continuous supply, allowing oxygen bottles to last up to three times as long. 5

A 1,000-bed hospital could potentially save up to £200,000 per annum on wasted oxygen – up to two-thirds of current expenditure. 5

References: 1. British Thoracic Society Emergency Oxygen Audit Report National Audit Period. Ronan O’Driscoll. 15 August – 1 November 2015 . 2. Data on file  – IMOS: Expert medical Reactions. Received September 2017. 3. Camcon Medical Ltd – IMOS – User manual (prepared by EG technology). 25 September 2017. 4. Camcon Medical Ltd – IMOS – Performance overview (prepared by EG technology). 25 September 2017. 5. IMOS Device: Clinical Insight and Technical Validation Report. Cambridge University Hospitals NHS. June 2014.